A movement to promote and conduct research on the treatment and prevention of drug-resistant tuberculosis, with a commitment to address the substantial existing gaps in our knowledge and to help provide access to an effective cure and prophylaxis of drug-resistant tuberculosis throughout the world.
Nearly nine million people will develop tuberculosis (TB) in the world this year; at least 500,000 of these cases will have multidrug-resistant tuberculosis (MDR-TB). Some will receive treatment. However, we know little about the best ways of treating drug-resistant TB (DR-TB) and preventing tuberculosis in people who come in contact with DR-TB patients. Lacking a strong scientific basis in prescribing treatment regimens, existing TB treatments are often ineffective. TB control efforts require new evidence-based knowledge about optimal treatment regimens, prophylaxis, and, possibly, regimens involving new TB drugs, in order to address the growing health threats of MDR-TB and extensively drug-resistant (XDR) TB.
TWO NEW MDR-TB TRIALS ANNOUNCED, TO START EARLY 2015
At the 45th World Conference on Lung Health, two new MDR-TB clinical trials were announced. The first, an expansion of the STREAM study called STREAM Stage 2 will compare a six-month bedaquiline containing regimen and a nine-month bedaquiline-containing regimen without an injectable to the current WHO standard of care and a modified Bangladesh regimen. STREAM Stage 2 will take place in Ethiopia, Mongolia, South Africa and Vietnam. The second new trial, NExT, will take place in South Africa and will compare a a 6-9 month injection-free regimen containing bedaquiline, linezolid, levofloxacin, ethionamide/high dose INH, and PZA to the current South African standard MDR-TB regimen. For more details visit our Clinical Trial Progress Report here.
Recent News and Announcements
Several organizations and individuals came together in September to write a letter to Janssen Pharmaceuticals, the maker of bedaquiline, to lower pricing for all non-high-income countries. Although bedaquiline is the first new TB drug approved in 40 years, it is not accessible to patients and TB program who need it most. Following the letter, Janssen responded […]
Treatment Action Group has released two new guides for activists on the use of delamanid and linezolid. These resources are intended to guide activists in what they can do to ensure access, fair pricing and further research. Access the delamanid guide here and the linezolid guide here on Treatment Action Group’s website.
Novartis has signed a licensing agreement with the Global Alliance for TB Drug Development for compounds to fight tuberculosis discovered at Novartis Institutes for Tropical Diseases (NITD). Under this agreement, NITD will transfer its TB R&D program to the TB Alliance, including research, development, approval and distribution responsibilities. Read more on the Novartis website here.
RESIST-TB has been awarded support from the Firland Foundation for a project proposal entitled “Monitoring Compassionate Use of New TB Drugs for MDR-TB and XDR-TB.” The project aims to survey high-burden countries and assess the demand for compassionate use in these areas, identify barriers to access, publicize these barriers, and propose potential ways to increase […]
Johnson & Johnson’s affiliate Janssen Pharmaceutica NV (Janssen) has entered into a collaboration with Stichting International Dispensary Association (IDA) which is a procurement agent for the Stop TB Partnership’s Global Drug Facility (GDF) to facilitate access to the Company’s anti-tuberculosis medicine. More than 130 low- and middle-income countries outside of the United States will now […]